300 likes | 328 Views
Rational application of flow cytometry in allergy. Didier EBO Immunology – Allergology – Rheumatology University of Antwerp - Belgium. IgE-mediated allergy: diagnosis. History Specific IgE (CAP) Skin test Mediator release assays histamine leukotriene Challenge tests.
E N D
Rational application of flow cytometry in allergy Didier EBOImmunology – Allergology – RheumatologyUniversity of Antwerp - Belgium
IgE-mediated allergy: diagnosis • History • Specific IgE (CAP) • Skin test • Mediator release assays • histamine • leukotriene • Challenge tests All have draw backs None absolute Additional tests
FCM in Barcelona • 4 sessions: • 9/6 Practical course: Cellular in vitro tests (119). • Principles and clinical applications • 10/6 Basic Plenary Symposium 3: Allergy diagnosis and monitoring (211/212) • 10/6 In vitro allergy diagnosis (117). • Drug allergy • 10/6 (19h) EuroBAT Working group meeting (CCIB 124/125) • Drug, venom and food allergy • Over 30 abstracts
Drug allergy • 15% ADR • > no IgE available • Skin tests • Culprit, cross-reactive compounds, alternatives • Serial dilutions (SPT, IDT) • Provocation tests
Stimulus Ref test Sens Spec N Ref -lactam H + ST 50 93 88 Sanz M, CEA 2002 -lactam H + ST + IgE + PT 49 91 110 Torres M, CEA 2004 -lactam 67 100 100 79 41 Abuaf N, CEA 2008 Metamizol H + PT 42 100 55 Gamboa P, Allergy 2003 NSAID H + PT 15-55 74-100 90 Gamboa P, CEA 2004 NMBA H 64 93 50 Abuaf N, JACI 1999 NMBA H + ST 54 100 60 Monneret G, Clin Imm 2002 NMBA H 79 100 24 Sudheer P, Anaesth 2005 NMBA H + ST 36-86 93 92 Kvedariene V, Allergy 2006 Rocuronium H + ST 92* 100 22 Ebo D, Allergy 2006 NSAID: non steroidal anti-inflammatory drugs NMBA: neuromuscular blocking agent * Including non-responders: 76%
Rocuronium • NMBA • 2 NH4+ epitopes • Severe (life-threatening) anaphylaxis • Cross-reactivity • Diagnosis > skin tests • BAT • sIgE
Group N History Skin test Controls* 21 + _ Allergics 24 + + NMBA controls* 18 + (other nmba) _ * Other cause (e.g. NRL, dyes, chlorhexidine, …) Rocuronium
17/21 (3 non-resp) 81% 71% ROC 4% 21 24 18 rocu - rocu + nmba Adapted from: Ebo DG et al, Allergy 2006
ROC 4% 21 24 18 rocu - rocu + nmba Adapted from: Ebo DG et al, Allergy 2006
* * neg. skin test rocuronium, pos skin test vecuronium
Individual cases • Chlorhexidine • Rifamycin • Pentastarch, succinylated gelatin • Heparin and LMWH • Patent blue • Hyaluronidase • CsA (cremophore: polyethoxylated castor oil) • Recombinant Hep B vaccine • Valcyclovir • Prednisolone
Ebo DG et al, Allergy 2005;60:703-704 Ebo DG et al, Allergy 2005
Non-responders • Adults: 5-10% (patients, control individuals) • Children: ? • Irrespective applied marker • CD63, CD203c, pp38 MAPK (preliminary data) • Should be mentioned in publications !!! • Individual: test is lost • Studies: false-negatives
Non-responder: refractory status • 4-6 weeks
Non-responders: drugs • In vitro (supra therapeutical): yes • Desloratadin, promethazin • Atorvastatin, cervistatin • Majlesi Y, J Leuk Biol 2003 • In vitro (therapeutical): no • Desloratadin and glucocorticosteroids • Krauzelbinder et al. EAACI 2008 abstract 54.
Gating the wrong cell See also Abuaf N, CEA 2008
Expression of activation marker • CD63: bi-modal • CD203c, pp38 MAPK: homogeneous
Drug allergy: • Diagnostic • Cross-reactivity • Alternatives • Combination of markers Complementary to other tests Absence of other tests Equivocal, false neg. results Less provocation tests